Requirement of TNF and TNF receptor type 2 for LPS-induced protection from lethal septic peritonitis

被引:22
作者
Echtenacher, B [1 ]
Männel, DN [1 ]
机构
[1] Univ Regensburg, Inst Pathol & Tumor Immunol, D-93042 Regensburg, Germany
来源
JOURNAL OF ENDOTOXIN RESEARCH | 2002年 / 8卷 / 05期
关键词
D O I
10.1179/096805102125000696
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pretreatment of mice with low quantities of LPS induces endotoxin tolerance characterized by enhanced resistance to lethal doses of LPS and to a number of infectious challenges. Mice subjected to cecal ligation and puncture (CLP) survived the ensuing septic peritonitis significantly better when they had been pretreated with LPS. This LPS-induced protection was dependent on endogenous TNF production capacity since LPS pretreatment did not protect TNF-deficient mice from death after CLP. While mice deficient in the TNF receptor type 2 (p75TNFR) were as sensitive to CLP-induced mortality as control mice, LPS pretreatment could not reduce mortality in p75TNFR-deficient mice after CLP. Therefore, activation of the TNF receptor type 2 by endogenous TNF constitutes an important interaction for the development of LPS-induced resistance to bacterial infection.
引用
收藏
页码:365 / 369
页数:5
相关论文
共 26 条
[1]   75-KDA BUT NOT 55-KDA TUMOR-NECROSIS-FACTOR RECEPTOR IS ACTIVE IN THE HOMOTYPIC AGGREGATION AND PROLIFERATION OF HUMAN LYMPHOKINE-ACTIVATED T-KILLER (T-LAK) CELLS IN-VITRO [J].
ABE, Y ;
YAMAUCHI, K ;
KIMURA, S .
JOURNAL OF LEUKOCYTE BIOLOGY, 1995, 57 (03) :462-468
[2]  
ECHTENACHER B, 1990, J IMMUNOL, V145, P3762
[3]   Differences in innate defense mechanisms in endotoxemia and polymicrobial septic peritonitis [J].
Echtenacher, B ;
Freudenberg, MA ;
Jack, RS ;
Männel, DN .
INFECTION AND IMMUNITY, 2001, 69 (12) :7271-7276
[4]  
Echtenacher Bernd, 1995, Journal of Inflammation, V47, P85
[5]   DECREASED SENSITIVITY TO TUMOR-NECROSIS-FACTOR BUT NORMAL T-CELL DEVELOPMENT IN TNF RECEPTOR-2-DEFICIENT MICE [J].
ERICKSON, SL ;
DESAUVAGE, FJ ;
KIKLY, K ;
CARVERMOORE, K ;
PITTSMEEK, S ;
GILLETT, N ;
SHEEHAN, KCF ;
SCHREIBER, RD ;
GOEDDEL, DV ;
MOORE, MW .
NATURE, 1994, 372 (6506) :560-563
[6]  
Feterowski C, 2001, EUR J IMMUNOL, V31, P1268, DOI 10.1002/1521-4141(200104)31:4<1268::AID-IMMU1268>3.0.CO
[7]  
2-C
[8]   THE TRANSMEMBRANE FORM OF TUMOR-NECROSIS-FACTOR IS THE PRIME ACTIVATING LIGAND OF THE 80 KDA TUMOR-NECROSIS-FACTOR RECEPTOR [J].
GRELL, M ;
DOUNI, E ;
WAJANT, H ;
LOHDEN, M ;
CLAUSS, M ;
MAXEINER, B ;
GEORGOPOULOS, S ;
LESSLAUER, W ;
KOLLIAS, G ;
PFIZENMAIER, K ;
SCHEURICH, P .
CELL, 1995, 83 (05) :793-802
[9]  
Grell M, 1998, EUR J IMMUNOL, V28, P257, DOI 10.1002/(SICI)1521-4141(199801)28:01<257::AID-IMMU257>3.0.CO
[10]  
2-G